Molecular Partners moves MP0712 to higher dose in Phase 1/2a study

Molecular Partners AG reported its H1 2026 financial results and corporate highlights on August 25, 2026. The company said its DLL3-targeting Radio-DARPin MP0712 has moved to the next therapeutic dose level, cohort 2, in the Phase 1/2a study.¹

In the trial, tracked under NCT07278479, the first dose level, cohort 1, is fully recruited, and repeat dosing is ongoing, with patients receiving as many as four doses of MP0712 so far.¹ The company said all patients in cohort 1, dosed at 75 MBq per dose, completed the safety observation period with no dose-limiting events.¹ It added that every adverse event reported so far has been mild to moderate, grade 1 to 2, and temporary, clearing up before the next scheduled dose.¹ Based on that safety data, the Dose Escalation Review Committee cleared the company to begin dosing cohort 2 at 105 MBq per dose, which is now open and enrolling patients.¹ Five of a planned nine study sites are currently active, and the Phase 1 portion includes four total dose levels.¹ The company said it expects to report initial clinical data in 2026, with a fuller safety and efficacy dataset to follow in 2027.¹

Separately, the company said it has selected CD70, a clinically validated tumor antigen overexpressed in clear cell renal cell carcinoma and other cancers, as the third target for its radiopharmaceutical pipeline.¹ IND-enabling work is set to begin in the second half of 2026, with clinical entry planned for 2027.¹

On finances, the company reported cash and cash equivalents of CHF 67.9 million as of June 30, 2026, net cash used in operating activities of CHF 25.0 million in H1 2026, an operating loss of CHF 27.0 million, and a net loss of CHF 26.7 million, with funding expected to last into late 2027 excluding potential R&D partnership payments.¹